Sub-membrane microtubule array, known to prevent excessive glucose-stimulated insulin secretion, depends on kinesin-1 KIF5B, which moves microtubules to both generate and remodel this array, ...
Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2025 and the completion of ESSENCE, its global, Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback